108 related articles for article (PubMed ID: 11316045)
1. Clinical associations and prognostic significance of serum anti-p53 antibodies in Thai patients with hepatocellular carcinoma.
Tangkijvanich P; Janchai A; Charuruks N; Kullavanijaya P; Theamboonlers A; Hirsch P; Poovorawan Y
Asian Pac J Allergy Immunol; 2000 Dec; 18(4):237-43. PubMed ID: 11316045
[TBL] [Abstract][Full Text] [Related]
2. [Prevalence and prognostic value of serum anti-p53 antibodies in hepatocellular carcinoma. A study of 159 patients].
Sitruk V; Vaysse J; Chevret S; Ganne-Carrie N; Christidis C; Trinchet J; Beaugrand M
Gastroenterol Clin Biol; 2000 Dec; 24(12):1159-63. PubMed ID: 11173728
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma.
Saffroy R; Lelong JC; Azoulay D; Salvucci M; Reynes M; Bismuth H; Debuire B; Lemoine A
Br J Cancer; 1999 Feb; 79(3-4):604-10. PubMed ID: 10027337
[TBL] [Abstract][Full Text] [Related]
4. Value of serum anti-p53 antibodies as a prognostic factor in Egyptian patients with hepatocellular carcinoma.
Atta MM; el-Masry SA; Abdel-Hameed M; Baiomy HA; Ramadan NE
Clin Biochem; 2008 Oct; 41(14-15):1131-9. PubMed ID: 18616935
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of p53 antigen and anti-p53 antibodies in the sera of hepatocellular carcinoma patients.
Charuruks N; Tangkijvanich P; Voravud N; Chatsantikul R; Theamboonlers A; Poovorawan Y
J Gastroenterol; 2001 Dec; 36(12):830-6. PubMed ID: 11777211
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of serum biological markers in patients with hepatocellular carcinoma.
Parasole R; Izzo F; Perrone F; Pignata S; Galati MG; Leonardi E; Castiglione F; Orlando R; Castello G; Esposito G; Gallo C; Daniele B
Clin Cancer Res; 2001 Nov; 7(11):3504-9. PubMed ID: 11705869
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma.
Shiota G; Kishimoto Y; Suyama A; Okubo M; Katayama S; Harada K; Ishida M; Hori K; Suou T; Kawasaki H
J Hepatol; 1997 Oct; 27(4):661-8. PubMed ID: 9365042
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the pattern and prognostic implications of anti-p53 in hepatocellular carcinoma.
Akere A; Otegbayo JA
Singapore Med J; 2007 Jan; 48(1):41-4. PubMed ID: 17245515
[TBL] [Abstract][Full Text] [Related]
9. Serum P53 Abs in HCC patients with viral hepatitis - type C.
EI-Emshaty HM; Gadelhak SA; Abdelaziz MM; Abbas AT; Gadelhak NA
Hepatogastroenterology; 2014 Sep; 61(134):1688-95. PubMed ID: 25436364
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma.
Maehara Y; Kakeji Y; Watanabe A; Baba H; Kusumoto H; Kohnoe S; Sugimachi K
Cancer; 1999 Jan; 85(2):302-8. PubMed ID: 10023696
[TBL] [Abstract][Full Text] [Related]
11. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
Gumus E; Erdamar S; Demirel G; Horasanli K; Kendirci M; Miroglu C
Int J Urol; 2004 Dec; 11(12):1070-7. PubMed ID: 15663677
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
13. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
14. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer.
Rosenfeld MR; Malats N; Schramm L; Graus F; Cardenal F; Viñolas N; Rosell R; Torà M; Real FX; Posner JB; Dalmau J
J Natl Cancer Inst; 1997 Mar; 89(5):381-5. PubMed ID: 9060960
[TBL] [Abstract][Full Text] [Related]
15. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.
Peng SY; Chen WJ; Lai PL; Jeng YM; Sheu JC; Hsu HC
Int J Cancer; 2004 Oct; 112(1):44-50. PubMed ID: 15305374
[TBL] [Abstract][Full Text] [Related]
16. [Correlation between serum anti-P53 and familial clustering of hepatocellular carcinoma in Guangxi].
Pang Y; Li GJ; Wu JZ; Wu JL; Chen WQ; Ning QY; Wei YH; Hu DF; Qin L
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Apr; 29(2):206-9. PubMed ID: 22487835
[TBL] [Abstract][Full Text] [Related]
17. Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma.
Ryder SD; Rizzi PM; Volkmann M; Metivier E; Pereira LM; Galle PR; Naoumov NV; Zentgraf H; Williams R
J Clin Pathol; 1996 Apr; 49(4):295-9. PubMed ID: 8655704
[TBL] [Abstract][Full Text] [Related]
18. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status.
Volkmann M; Müller M; Hofmann WJ; Meyer M; Hagelstein J; Räth U; Kommerell B; Zentgraf H; Galle PR
Hepatology; 1993 Sep; 18(3):559-65. PubMed ID: 7689531
[TBL] [Abstract][Full Text] [Related]
19. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and clinical relevance of serum anti-p53 antibodies in patients with cholangiocarcinoma.
Tangkijvanich P; Kasemsupatana K; Janchai A; Kullavanijaya P; Theamboonlers A; Poovorawan Y
Asian Pac J Allergy Immunol; 2000 Sep; 18(3):173-6. PubMed ID: 11270475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
